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After coronary artery bypass surgery, 16% to 31% of saphe- 
nous vein grafts fail within 1 year, and 40% fail by 10 years 
(l-4). Moreover, 81 10 years only 33% of vein grafts ere 
found to be angiographicelly free of lumen stenoses (5). Vein 
~raf* Ulure is thus a major cause of the recurrent or 
worsening symptoms that develop annually in 4% IO 9% of 
prqmw*dbrdtu. 
(I All cdl Enw lsPd;u:lm4u) 
@ants after bypiw sowry (a-9). Althou& a xeond bypops 
surtwy is Swxally aa option, it is associated with as hi as 
II% in-hospital mortality rata (10-18) aad a !O% it&aace 
of priopslative myowdii infarction (10.17.19.20). Con- 
vcntiottal balloon aagioplarty of focally dirasad @alIs may 
be another altemative, but psliants tmder~oioing dilation of 
graRs>3ycars~ddhPveuptoa4%m~tyratcandal290 
pariprocedural myocardii infarctioa rata (20). II is particu- 
My disappointing that up to 68% of ~raks treated with 
balloon angioplasty developatt&gaphic nsteaosis within6 
months after the procedure (21). 
The use of newer interventioaal devices (such as the 
coronary stent w direct&al athercctomy) lo treat selected 
native coronary lesions can provide excellanl imawdiate 
results, aad preliminary data suggest a reduction in tbe 
incidence of aatdographic nstenosis (22.23). Whether lbcsa 
devices offer skilar benefits in the treatment of dire& 
vein arafts is still in ouestioo. Since Jum 1988. WI ceater 
has t&ated ZM) vein &aft lesions using Palmaz&hatz stems 
(146 with coronary and 54 with biliary stents) in IS0 patients. 
This report describes the immediate and the long-term 
angiographic and clinicai results in these patients. 
Methods 
an investigational Device Exemption &n&d by the Food 
Study ptl+os. Between Ju e 1988 and April 1993, Pa- 
maz-Schatr coronary stems (Johnson & Johnson Interven- 
and Drug Administration (FDA). Between May 1992 and 
tlonal Systems) were used to treat I45 vein graft stenosej in 
i I I &ants as par: of a multicenter studv, wformed under 
April 1993, an addiiional55 saphenous vein graft stenoses in 
44 o&n& were treated wine the FDA-aoomved Palmaz- 
with multiple (two or three) contiguous stertts were consid- 
ered to represent a single long stent for purposes of analysis. 
m&t. ws also recorded. Se&o c&ine kinase (CK).and a 
All patients were assessed repeatedly by the investigators 
for the development of major vascular complications, de- 
12.lead electrocardiogram were obtained in all patients af!er 
fined as hemorrhage, hematoma, pseudoaneurysm or arte- 
riovenous fistula necessitating surgical repair, retroperito- 
the procedure and again the next morning. Myocardial 
n-21 twnorrtug* 0r transfusion. Thir zl5se58mc”t insluded 
cross correlation wifh wolfs from vascular surgery and 
infarction was defined as anv elevation of CR >?tlO IUiliter. 
transfusion records to detect any complications that oc- 
curred later during the hospital period or after discharge. 
Anv transfusion during the hospital period, after stent place- 
_~ ~~ 
Schatz biliaty stent (John& & Johns;; Interventional with ~5% IMB isoforms. 
Systems) for this unappmved indication (24). Both devices Medical regimen. All patients were pretreated with aspi- 
were used under investigational protocols approved by the rin (325 mdday). dipyridamole (50 mg four times a day) and 
Institutional Review Board of Beth Israel Hospital. and dextran-40 <IGil mUh beginning 3 h before the procedure). 
iafomred consent was obtained from all patients. Five pa- Antibiotic prophylaxis (cefazolin, I s/p h) was administered 
tienrs with biii stents had previously received a coronary before and for 48 h after the procedure. An initial intrave- 
stent for treatment of saphenous vein graft stenoses. A total now heparin bolus dose of 10.000 U was given atIer place- 
of 280 saphews vein graft lesions were thus treated during meat of the arterial sheath. and additional heparin was 
164 sewate omceduns in IS0 oatients. titrated to maintain an activated clotting time >300 s before 
ihmmbus unres&sive to &&nbolysis was also a rel&ve 
~. ~. 
corttmindiition to stem placement. Patients were also de- 
All patients had evidence bf myocardial ischemia by 
nied stenting if clinical contraindications to aegressive anti- 
either exercise treadmill testing or spontaneous ischemia at 
co@rmt thetapy existed. Overall, the current series of ZOO 
vein grsR slents represents 54% of ail saphenous grail 
rest. Advanced age, unstable anpina. congestive heart fail- 
interventions performed in our laboratory during the study 
period. 
we. previous myocardial infarction, long lesion length or 
previous vein 8t-aft dilation did not preclude participation. 
Diffuse 8raf1 disease. defined as individual lesion lenpth 
>28 mm, was considered a relative contraindicalion to 
scenting, altlm@ seven such lesions were treated. The 
aresonce of hllinn defects sunaesdve of extensive intraarall 
S&B! #aeemaat. The procedures for deploying either the 
articulated coronary or biliary stent have been described 
elxwhc~ (24-28). Most coronary stents were delivered 
using an integrated 5F sheath system containing the IS-mm 
long stent premounted on a delivery balloon (inflated diam- 
eter 3.0, 3.5 or 4.0 mm; Stent Delivery System, Johnson & 
Johnson Interventional Systems). The diameter of the de- 
ployed coronary stem could then be enlarged further (up lo 
5 mm) by i&tiin of a latger convendonal angioplasty 
bailova within the stent. Biliary stents were delivered by 
crimping them onto peripheral attgioplasty balloons (4.0,4.5 
or 5.0 mm; Schwarten, Peripheral Systems Group) and by 
dilating rhem further (up lo 6 mm) when necessary. Biliary 
stems were 10, 15 or 20 mm in length (the nonarticulated 
PI@& PI54 or the articulated PQW: Johnson 8r Johnson 
afier sheath removal to maintain an activated patlial throm- 
boplnstin time of70 to 90 s until pmlongation of prothrombin 
stem placemem. Intmcomnary ver&mil (2M to 400 ~8) 
time to 16 lo I8 s (international normalized ratio Of 2.1 to 
3.4). Worfarin (IO mg orally) was given the day of or the 
and inrncoronary nitroglycerin (200 rcg) were used to treat 
evenina mior to the procedure and was then titrated to 
prolong prothrombin &ne to the desired level before dis- 
episodes of transient reduction in distal Row after stettt 
charge from hospital. Warfarin was discontinued 6 to 8 
weeks after hospital discharge, but all patients continued to 
placement when required (29). Dextran-40 administration 
receive aspirin and dipyridamole indefinitely. Antibiotic 
oroohvlaxis for bacterial endocarditis was recommended for 
was continued at a rate of 20 mVh for IS to 20 h after stent 
;nv’ d&d manipulation or invasive procedure performed 
wiihin 8 weeks &ter stem placement. 
placement. After stem deployment, no further heparin infu- 
sion was administered, and sheaths were removed once the 
activated clotting titx had decreased to 180 E. intra+znous 
heparin was then resumed at NM U/h (without a bolos) 2 h 
Followm. All 147 ordients with successful stent deploy- 
ment had clinical follow-up performed by the investigat&s at 
2 months, 6 months and yearly to assess clinical events 
(death, myocardial infarction or any revascularization pro- 
cedure [bypass surgery or coronary angioplastyl). Available 
clinical data and follow-up angiograms were also reviewed lo 
determine whether an event could be attributed to failure of 
the stented vessel (“target vessel failure”) and, more spe- 
cifically. to failure of the stented site (“target site faik”). 
Any lumen renarrcwing that either required clinically driven 
Interventional Systems). Six of the longer lesions treated rev&darization (by a percutaneous procedure or bypass 
surgery) or caused a late myocardial infarction in the teni- 
tory supplied by the stenled vessel was considered a clinical 
failure of the target site or the target vessel, Y described 
earlier. 
Aqdograpbkmmiysls. Each stented lesion was measured 
with diital calipxs (Fowkr Ultra-Cal II) from an optically 
magnified image of the single view showing the most severe 
stenosis, using the 9F (3.~mm) guide catheter as a reference 
object (28). Baseline measurements included minimal lumen 
diameter before conventional coromuy angiopksty and 
matched views after stem placement. The diameters of the 
proximal and distal reference segments were averaged to 
yield a mean reference diameter. The first 93 consecutive 
patients (with I20 lesions) with successful stcntiog were 
asked to return for aogiographic assessment of stem patency 
at 3 to 6 months after the procedure (the engiogmphic 
cohort). Repeat aogiography wasobtained for 94 oflhesc I20 
lesions (78% angiographic follow-up). Restcnosis was de- 
fined as lumen diameter stenosis ~50% within or immedi- 
alelv adjacent lo the stem. Follow-uo measurements of each 
st&tedx?gment were routinely mad; in the same view used 
for the baseline angiogram, unless mstenosis occurred in an 
eccentric fashion that was belter visualized in the orthamnrd 
view. In no instance did the orthogonal view demonstrate 
rcslenosis when the original projection utilized for follow-up 
angiographic measurements did not. ARer the first 93 pa- 
tients. for both financial and loeislic considerations. we did 
not require that subsequent asymptomatic patients return for 
restudy. 
Statktkrd mmlysis. Data were expressed as mean value f 
SD. The association between restenosis (defined as aSCr% 
diameter stenosis) and categoric or continuous variables was 
performed by using the chi-square test and analysis of 
variance respectively. Event-free survival rate after stem 
placement was estimated using Kaplan-M&r techniques 
and was displayed as standard survival curves. Differences 
in event-free survival rate were assessed by the logmnktest. 
Rtka ELurcnhtkr. Baseline demogmphiis of the 
study gro”p are sbowo in Tabk I. Sapbeoous vein byws 
gaAehadsmeaa~d8.7-C4ycarJ,with~%>3yean 
old (T&k 2). Multiveswl ammary artery disease was 
oresent in97% dcatkots. most ofwbom badeitbernnxnt 
myocardial info&m or unstable angina. Twenly-cight per- 
cell of patknts had under&me prvio”s balloon aogkpksty 
at thx pkmxd sterdiog site. 
llrdv e. Baselii maphologk features of 
thetreatedvek@tksknsaresummarWinTabk2. 
Angio8nphii evideltce of tllmmbus was prsent in 16% of 
lesionstrured.Plld4996WeRCCEenlTie.~meanrdrrcnee 
graft dkmekr and mean vnt stenosis diier 
Wre 3.72 f 0.81 and 0.98 * 0.58 mm, aspcctively, tale- 
spondiitonmeaodkmeterstemsisd74~ M%.Mean 
krko kngth was 7.81 2 5.6 mm, with a maximal ksion 
length of44.7 mm. Lesion ko#h wee al0 mm in 44 krkns 
(18inthca&+mphiicohal~.ofwhkh7(2intheangk+ 
gmphii cohort) were 220 mm. 
- rmib. stat deployment was s”ccersf”l in 
l97of2Mtatkmpts(98.5%pkcement suecns)andincreased 
the minimal lumendiiterat the treatment site fromO.9B + 
0.58 to3.65 * 0.67 mm, ykldiegaresidualdiitcrstcoosis 
of I -2 15%. Am”n# “ns”ccn&l placements. “UC E”mnaly 
stem was delivered but could not be cokrged ~-2 mm despite 
balloon i&tioe to X0 atm. Dne bilii stem was success- 
fully placed IO tnat abrupt closure ased by atteropled 
tal to the &, &ing retrograde thmmbosir of ik graft 
with non-Q wave myocardkl infarction (CK 606 Wliter. 
with 15% MB tiaction). Doe biliarv stem could oat be 
delivered to the large1 site and was ~bsequeotly embolized 
(without clinkal sequeke) during attempted withdrawal into 
the guide calbeler. Thus, I97 stenls were susccssfully placed 
in 147 patients during 161 procedures. 
M the 147 successfully treated patients, 32 required 
multiple stems placed d”riog a siogk procedure. This in- 
cluded two patients who had single stats placed io two 
separate vein grafts during the same procedure. Multipk, 
Tabk3. In-HosDifal Rccedunl Camolications in IM Procedures 
aonconliguous stems were deployed in a single saphenous 
vein gratl in 24 patients (2 stents in 22 graRs. 3 stems in 2 
grafts), whereas multiple (2 or 3) contiguous stents were 
deployed in 6 patients. 
Co&k&m. Major comolicatians (death. Q-wave my- 
ocardiai infarction. &erg& bypass) occur&in t (0.6661 
of 164 pmceduns (I death). This death occurred ia a patient 
who had sustained two non-Q wave myocardial infarctions 
during the week before steal placement. This patient died of 
ventricular fibrillation in the absence of chest pain 6 days 
afler stenting and did not undergo postmortem examination. 
One acute thrombosis occurred (as described earlier). but 
there were 110 subacute thromboses. Twelve (7.3%) of 164 
procedures were complicated by CK increase (mean CK 519 
lU/liter. range 242 to 955 W/liter), aooe of which were 
associated with the evolution of Q waves. Only seven of 
these (4.3%) were associated with CK-MB SO W/liter. the 
minimal level that we have observed to be asswiated with 
any reduction in long-term survival after an otherwise suc- 
cessful intervention(3OL One patient with unsuccessful stem 
placement (inability to expand the steal adequately. as 
described earlier) underwent nonemergent coronary artery 
bypass surgery 21 days later. Another patient with success- 
ful stent placement had nonemergent coronary artery bypass 
surgery 2 days later for unstable angina due to disease in 
aaother gratt. with angiography before operation demon- 
strating wide patency of the stented graft. One patient 
develowd transient cortical blindness several hours after the 
pro-&e (presumably due to aa embolic stroke). and one 
patient developed an intracranial hemonhage 4 days after 
stent placement, with no long-term sequelae after successful 
aeumsurgical evacuation. 
Stentiog was followed by vascular complications requir- 
ing operation in I4 (8.5%) of I64 procedures (Table 3). This 
Table 4. Characteristics of Patienrs and Lesions With and 
Wirhout Rrrtenoris in Angiagfdphic Cohort (n = 94 lesions) 
Rerktwir NO Rerlcoosir 
I” = 101 I” = ,B nvalae 
included eight femoral pseudoaneurysms (4.9%). three ane- 
riovenous iistolae (1.8%), two arterial lacerations (I .2%) and 
one femoral artery thrombosis (0.6%). There were three 
retmperitoneal hemorrhages (1.8%). and transfusion (exclu- 
sive of other vascular complications) was required in 23 
patients (l4%l at some time during the hospital pried after 
swat placement. Hwever, no patient had long-term se- 
quelae from these vascular complications. 
Angiegraphic lopOw-up. In the angiogmphic cohort (con- 
sisting of the first 93 consecutive patients, who were asked to 
return for repeat angiography at 3 to 6 months), angiographic 
follow-up was obtained for 94 (78%) of 120 stented lesions at 
a mean of 7. I months after the procedure. Aagiographic 
restudy was perfomed between 6 months and I year after 
the procedure in 60 patients and 21 year atIer Seating in 4 
patients. with a maximal time to restudy of 802 days. 
Restencsis (defined as diameter stenosis ~50%) was present 
in 17% (95% confidence interval 9% to 25%) of lesions in this 
group. Further analysis showed that stenting provided a 
mean immediate gain of 2.69 t 0.78 mm, with a late loss of 
I. I8 -c I. I6 mm, for a mean late lumen diameter of 2.44 2 
1.02 mm (mean late lumen diameter stenosis of 31%). The 
mean loss index (the ratio of late loss/immediate gain) for 
stented vein grafts was 0.44. 
Demographic and morpholog;c characteristics of patients 
with and without restenosis in the angiographic cohort are 
summarized in Table 4. Patients with restenosis were slightly 
older and had somewhat older vein grafts, although these 
small differences failed to reach statistical sisnificance. 
Seven (29%) of 24 lesions in patients with diabetes axl!ii~ 
developed rcstenosis, compared with only 9 (13%) of 70 
lesions in nondiabetic patients (p = 0.07). The group that 
developed restenosis after stenting had a 25% prevalence of 
previous rester&s at the treatment site compared with a 
IS% prevalence in the group free of rcstenosis at follow-up. 
However, this trend also fatted to achieve statistical signiS 
cancc (p = 0.28) because of the small number of events. 
Other demographic variables, including gender, sernm cho- 
testerol, recent myocardial infarction and unstable angina, 
arc not associated with increased restenosir. 
Analysis of at&graphic characteristics in patients with 
and wi!!~out restenosis showed that lesions that developed 
restenosis tended to be longer (8.94 f 6.82 vs. 6.7 2 
4.17 mm, respectively, p = OHIO). Restenosis thus occurred 
in 15% of lesions <IO mm in length versus 27% of those 
a10 nun (p = 0.28). Conversely, 25% of the atented seg- 
ments that subsequently rcstcnosed had a lesicm length 
210 mm compared with 14% of those without restenosis at 
angiographic follow-up (p = 0.28). Among patients with 
multiple sterns in a single graft, the lesion-based restenosis 
rate of 17.7% comnarcd closely with the 16.9% rate in 
vessels treated with usingle stent\p = 0.94). However, three 
(43%) of the seven patients with multiple stents in a single 
graft (17 stented segments) developed rcstenosis at some 
location in the graft compared with 18% of palients with only 
a single stented segment (p = 0.12). Other geometric char- 
acteristics of the lesion. such as reference vein diameter, 
minimal lumen diameter before or after stenting or prep*+ 
cedural percent stenosis, were similar in patients who did 
and did nor develop restenosis. 
The use of biliary stents began aRer enrollment of the 
angiographic cohort had been completed. In the group 
treated with biliary stents. angiograpbic restudy was even- 
tually performed in 13 of55 le&ts. with a restewsis rate of 
23% compared with 17% for coronary stents overall (D = 
0.64). These patients were not part-of the at&graphic 
cohort and generally underwent restudy because of recur- 
rent symptoms; therefore, this rate probably somewhat 
overestimates the incidence of restctwsis for the biliary stent 
cohort as a whole. Similarly, patienls who received tandem 
stents did so after the routine angiographic follow-up cohort 
was recruited. Of the four patients with tandem stentr that 
were not restudied at I06 to 187 days, two of four patients 
demonstrated restenosis that was successfully treat-d with 
balloon angioplasty. These two patients remained asymp 
tomatic at 266 and 339 days of follow.up, as did the two 
patients with tandem stems who did not undergo restudy. 
Clinical R~Itow-up. Clinical follow-up was obtained in 145 
(99%) of 147 successfully treated patients at a median of IS.5 
months. During the follow-up period, 49% of patients had a 
cardiac event (late myocardi&infarction, rcvarculatization, 
deathl. Twentv natients died (14%). includinn I4 tIO%I who 
died if cardiaceauscs. Sixteen patients (11%) sustained a 
late myocardial infarctian. Repeat revasculariaation was 
performed in 39% and included balloon angioplasty in 35% 
FIgare I. Kaplan-Meier estimate5 of event-free survival rate for 
de&h. death or myccardiat infarction (MI) and any complication 
(death, myccardiat infarction. rcpcat revascutartzation) in 147 pa_ 
dents with ruceesrful bnt placement. 
grams, however, showed that only 25% of patients had 
evidence of target vessel fathue, and only 15% had failure 
within the stented site itself &vgct site failure). Among 
patients treated with bii stents with a mean duration of 
foltow-up of 138 2 62days &gc 44 10277). the target vessel 
failure rate tL?%) and the tame1 site failure t-ate (8%) were 
similar lo those observed aRei coronary stentittg. 
Kaplan-Meier survival analysis d&onstrated a cumula- 
tive 2-vear cardiac event rate of 57.4 2 5.1% @ii. Il. 
including a Z-year revascnlarlzatlon tate of 49.0 1 3.4%: 
beat&the &te of target vessel failure at 2 years was only 
34.1 f 4.1%andthe rateoftaraet site failure wasonly 22.1 z 
3.9%. the majority of revas&rt~tion proccd&s were 
thus related to progression of dhasc elsewhere. not to 
failure of the stented scgmcnt itself (Fit. 2). 
DiSCUS!iiOll 
Despite the excellent immediate rcsul~s of initial coronary 
artery bypass surgxy, saphenous vein graft failure and 
disease pmgressiott in the native ~mnnary circulation cause 
4% to 9% of patients to develop recurrent ixhcmic symp 
tams annually (6-W. As the number of patients with prcvi- 
cuts aortocomnary bypass has grown, the prevalence of 
recurrent angina due to gratt failure has increased. thus 
increasing the need for either repeat bypass surgery or 
pcrcutanews treatment. However, reDeat coronary artery 
bypass surgery has a substantially high& periopxat&e mar- 
tality and morbidily than initial operations (10-20) and is 
ass&&d with both a lower rate of anaina relief and a higher 
rate of subsequent graft failure (l3-75). Moreover, t&y 
patients are excluded from repeat coronary artery bypass 
and bypass surgery in 16%. Analysis of associated angio- surgery because of a lack of appropriate conduits. severe 
100 m coronary and biliaw stems for the treatment of saohenous 
Qure 1. Kaplan-M.+ estimates of event-free surwval rate for 
target site failure and target vessel failure in 197 lesions uccessfully 
stented. Target site failure was defined as any clinically d&u 
revsscula.rization. myacardiil infar0ion or death nttributvble to 
failun of the stented site. Target vessel failure was defined ns any 
clinically driven revascularization. mywudial infarction or death 
ettributabk to failure anywhere in the stented graft. For compari- 
son. the rate of reedom from revascularizetion for I47 patients with 
successful stem placement is also shown. 
comorbid disease or significantly depressed left ventricular 
function. The limitations of repat cornwry artery bypass 
sutwr~ for the ttwdmettf of failed vein malls have thus 
fuei~;ffonstodevelopefficaciws percutaneous techniques 
whereby patients with previous bypass surgery (undergoiug 
tt-eaiment of either a graft or native vessel) now constitute 
IO% to 2S% of conwary interventions id many institutions 
(31). 
Conventional ballam angioplnsty can be used to treat 
foeal stenoses in recently placed vein gmt7s with excellent 
immediate clinical success and a low rate of procedure- 
&ted complications (32). When performed in vein nmfts 
>3 years. h&ever. balloon angiopiasty can be accompkied 
by much higher procedural complication rates (up to IS%). 
showing the friable nature of late &atl atherosclerosis com- 
pared with the intimal hyperplasia found in younger vein 
grafl steooses (4,20.33-,351. Even successful vein graft au- 
giopkty still leaves a residual stenosis of 25% to 27% 
(34.36) and is followed by angiographie restenosis rates afas 
hii as 68%. with a correspondingly high incidence of late 
cardiac events (21.32). Endavascular stcnting has therefore 
been proposed as an alternative percutaneous technique for 
the mawtement of saphenous vein graft stenoses 125.37.38). 
It was tkmght that’the reduction in elastic recoil and 
retention of plaque against the graft wall by stenting would 
pmvidz a widely patent lumen with less abrupt closure, 
lower resteuosis rate and better late clinical outcome. The 
curre~~t report is the largest singk-center experience describ- 
ing immediate and long-term results using Palmaz-Schatz 
vein graft stenoses kd suggests that some of these’benefits 
may be obtained. 
Im-_-din!e remIts. The 98.5% success rate for deirlov- 
ment in our series of 200 saphenous vein graft ste&& 
waled rvirh Palmaz-Schatz coronary and bilim stents com- 
pares favorably with the 88% SUCC&S rate of l&Icon angio- 
plasty (32) and is similar to our own earlier results (251, the 
results with the Wallstent (9S% to IMMO success) and the 
U.S. multicenter experience with the Palmaz-Schatz corn-- 
new ~teot (98% success 137-391). Althounh one euisade of 
a& graft thrombosis (0.5%) did occur in-our study, it took 
place during an attempted salvage of a vein g&t after 
dissectton and during abrupt closure caused by initial bal- 
loon angioplasty. The low r&e of stem thmmbkis is partic- 
ularlv notable in that 16% oi treated lesions contained 
angi&-aphic evidence of thmmbus. 80% of patients had 
unstable angina. and three patients had sustained myocardial 
infarction within the 48 h before the pmcedure. In the 
Wallstent experience (40). such ocutc iscbemic syndmmes 
were found to be important risk factors for the development 
of stem thrombosis, which was observed in 10% of stented 
vein gr&s. Conversely, the aggressive anticoagulant regi- 
men we used to minimize stent thrombosis did contribute to 
a high incidence of vascular surgery r&S%) and transfusion 
alone (lJ%“,), as has been reported in other series of stenting 
1271. Althouch this increased both overall len.eth of smv and 
hospital cask. there were no long-term sequkae fro; VBS- 
cular complications in any patient. Improvements in vascu- 
lar closure techniques or the development of less thrombo- 
genie stents requiring less aggressk anticoagulation should 
temper this problem in the future. 
No patient in the current study required emergent com- 
nary artery bypass surgery, although two patients (1.3%) 
underwent nanemergent surgery duriy the initial hospital 
period. There were no pmceduml deaths, only one in- 
hospital death (0.6%) and no Q wave myocaniial infarctions. 
Although 7.3% of procedures were complicated by an in- 
crease CK levels consistent with non-0 wave infarction, 
only 4.3% involved an increase in CK-MB HO IUiliter. a 
level above which we have observed effects on long-term 
wvival (30). This low incidence of major complications is 
promising. considering the advanced graft age (mean age 8.7 
years, with 92% >3 years old) in this group. In addition to 
advanced graft age, other adverse angiagmphic features in 
our patients included thrombus-contk& lesions (16%), 
lesions >I0 mm in length (25%) and placement of multiple 
stems in a single vein graft (1%). Our immediate results 
thus compare favorably with conventional angioplasty de. 
spite the fact that angioplasty has generally been reserved 
for lesions with fewer adverse chancteristics. 
The magtutude of immediate lumen enlargement obtained 
by stenting was also better than that previously reported for 
conventional angioplasty. In previous studies, balloon an- 
gioplasty in saphenous vein grafts has typically achieved 
mean residual stenoses of 25% to 30% (34.36). More re- 
cently. mean residual stenoses of 23% to 24% have been 
rewrted with the Wallstent (39,40!. Using the Palmar- 
S&K coronary and biliary stents, however, we were able 
to achieve a mean residual diameter stenosis of I%. Tbeo- 
retieally, the larger postprocedural umen diameter achieved 
using Palmaz-Schatz stenting may help to explain the ap$ar- 
ent reduction in subsequent thrombosis and restenosis. The 
consistency of achieving this large portprccedural lumen 
diameter by stenting may also account for the lack of effect 
of pretreatment lumen morphology on procedural outcome. 
Although a similar degree of lumen enlargement of vein m 
stenoses may be obtainable with directional atherectomy. 
the immediate complications and late restenosis rates 
achieved with that device in vein grafts do not seem as 
satisfactory (41). 
A@g@ie restem&. With 78% angiogmphic follow- 
up in our predesignated cohort. we found a 17% rate of 
restenosis (95% confidence interval 9% to 25%). defined as 
aSG% late diameter stenosis. This reslenosis rate is lower 
than that reported for any other percutaneous treatment of 
saphenous vein grafts. In a recent review by de Peytcr et al. 
(?L), the overall restenosis rate after vein -&ft angioplasty 
war 42%. whereas the Multi-Hospital Eastern Atlantic Re- 
stenosis Trial (M-HEARTJ trial showed a restenosis rate of 
68% in vein gmfts (21). The lower 2056 to 40% restenosis 
rates in the European Wallstent exoerience (38-401 and the 
26% restenosis r&e in the U.S. m~lticenter~Pahnaa-Schatharz 
coronary slant registry (37) come closest to our observed 
restcnosis rate and lend further support to our impression 
that stenting may help reduce vein graft resteoosis compared 
with conventional angioplasty. This issue is now being 
addressed in a prospective randomized trial. 
The low incidence of angiographii restenosis in our study 
may primarily reflect the large caliber of the stewed vein 
grafts and the low residual s!enosis left a&r stcntiog. In a 
combined series of native corooary arteries and saphenous 
vein u&s treated with Palmaz-Schatz stentioa, Carrozaaet al. 
(27) previously reporled a higher rate of &&is when the 
postptweduml lumen diam&r was ~3.31 mm. supporting 
the findings of Ktmtz et al. (42) that a larger postprocedural 
lumen diameter in native coronary arteries is the strongest 
geometric predictor of freedom from angiographic resten& 
at 6 months after stenting, atherectomy or balloon angio- 
plasty. Because only 25% of our stented graRs had a 
postprocedural umen diameter d3.2 mm. and the number of 
restenosis events observed was small, it is not possible to 
evaluate further the relation between minimal lumen diame- 
ter after stenting and subsequent restenosis in the vein graR 
cohort. 
It is unlikely that the low restenosis rate achieved with 
stenting reflects the routine use of warfarin in our cohort. In 
a randomized trial comparing aspirin with warfarin for the 
prevention of restenosis after balloon angioplasty. Thamton 
et al. (43) have previously reported a restenosis rate of 36% 
with watfarin versus 27% with aspirin. Thus. although 
watfatin therapy has clearly reduced the incidence of acute 
and subacute thrombosis after Pelmaz-Schatz stenting (44). 
it would not be expected to inhibit smooth muscle pmliier- 
atioo within the stent or reduce long-term restenwis. 
Despite :he large postprocedural umen diameter and low 
angiogmphic restenosis rate achieved with steoting of vein 
gmfts, stented g&s deariy do experience si8niticant late loss 
(a reduction in lumen diameter between the end of the proce- 
due and follow-up angiogmphy) that averages 1.18 mm. Pre- 
vious studies have shown that late loss tends to be propor- 
tional to immediate gain, expressed by the loss index (the 
ratio of late loss/acute gain). as a measure of the proliferative 
ootential of a treated lesion. In the current study the loss 
index of 0.44 is within the range previously rep&d for the 
left anterior desceting coronary artery (0.52) and the right 
(0.35) coronary atlety (45). To the extent that the restenosis 
behavior after vein gmft stenting thus parallels that observed 
in native coronary arteries after a variety of other treatment 
modalities, the low restenosis tatcs that we observed pmb- 
ably reflect the consistently large postprocedural lumen 
diameter obtained by stenting rather than any modiition 
of the intinsic biology of resleoosis. 
Cliakd f&wnp. Despite a low at&graphic restenosis 
rate. late clinical events were frequent during follow-up. 
Although previous studies of vein gtal? aogioplasty (32) have 
shown relatively higher rates o: restcnosis requiting repeat 
revawlatization. 3CrZ of late events in the Eumoeaa Wall- 
stent experience were actually due to direax &gression 
elsewhere rather than restcnosis of the stented lesian (40). 
To separate late slent failure fum disease progression at 
other sites. we attempted to determine how many late 
clinical events were r&cd to failure of eilber the target 
veswl or the target site. Altiwttgh our 2-year Kaplan-Me& 
revaxularizatiw rate was 49%. the target vessel failwe mte 
was only 34%, and the target site failure rate was only 2.2%. 
closely matching the 17% incidence of bmonth angiogmphii 
resteoosis. This further supports a lack of clinical restewsis 
progression >6 months (Fig. 2) hut uttrkrscoccs the fact that 
whereas individual stewas in saphenous vein grafts are 
effectively treated by stent placement. patientswithdiwased 
vein gratis commonly require further interventions to man- 
age either vein graft degenetation at other sites or p-s- 
sion of native corooary disease. Even if we had completely 
eliminated restenasis by steming. 36% of patients with vein 
graft disease in this series would still have required repeat 
revascularizatioo within 2 years. 
Study Ilrwar. This study has several important limi- 
tations. The lack of a conventional balloon anpioplasty 
control group in o’w series precludes any direct comparison 
of stcttliog and balloon angioplasty. Even historical cornpar. 
isons may be hampered by a selection bias that excluded 
patients who had small or diffusely diseaxd gralts from 
stentinn. The results of the onaoina SAVED (Percutaneous 
Traosl~ntinal Coronary Angiop& Versus Coronary Stent- 
in8 of De Now Saphenous Vein Grafts) trial. a multicenter 
randomized, prospective trial comparing conventional bal- 
loon angioplasty with the Pahnaz-Schatz coronary stent for 
treatment of de now saphenous vein gr& stenoscs. must be 
awaited to provide direct cornpa& of the safety and 
ej%%y ofthese approaches. Another limitation of this study 
is Our we of diital calipers instead of computer-assisted 
quantitative anpiography. Previous comparisons of our tech- 
nique using optical magnification in a darkened room. bow- 
ever, have shown excellent agreement with computer- 
assisted angiogaphy (46,47). 
Cooch&a~~. Palmaz-Schatz coronary and biiiary stems 
can be used to treat focal saphenous vein graft stenoses with 
excellent immediate success. Despite an 8.5% incidence of 
vascular injury requiring surgic3i repair. major complica- 
tions were uncommon. even when treating alder gnfts with 
adVerse morphologic features. The 17% angiognphic resten- 
osif rate seen after such treatment is lower than that histor- 
ically reported for &Uoon angioplas~y, directional atherec- 
tomyorthe ‘Wls!ent. This low angiognphic restenosis rate 
is accompanied by a low I-year incidence of target vessel 
failure (34%) and target site failure (22%). However, late 
clinical events remain frequent (57% at? years). becouse of 
aggressive disease progression at other sites in this patient 
group. Ahho@ the SAVED trial results are needed to 
confirm the usefulness of this procedure. these early data 
suggest that the I’alnw-Schatz sent may be subslantially 
promising in the treatment of focal saphenous vein graft 
stenoses. 
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